Insider Transactions in Q4 2020 at Bei Gene, Ltd. (BGNE)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 29
2020
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-38.57%
|
$372,000
$248.87 P/Share
|
|
Dec 29
2020
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
Dec 18
2020
|
Amgen Inc > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
25,762
+0.14%
|
$6,698,120
$260.95 P/Share
|
|
Dec 17
2020
|
Amgen Inc > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
74,624
+0.4%
|
$19,402,240
$260.54 P/Share
|
|
Dec 16
2020
|
Amgen Inc > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
85,573
+0.46%
|
$21,222,104
$248.26 P/Share
|
|
Dec 15
2020
|
Xiaodong Wang Director |
SELL
Bona fide gift
|
Direct |
165,295
-2.82%
|
-
|
|
Dec 15
2020
|
Amgen Inc > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
67,941
+0.36%
|
$16,237,899
$239.31 P/Share
|
|
Dec 14
2020
|
Howard Liang CFO & Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
91,900
-32.44%
|
$20,953,200
$228.58 P/Share
|
|
Dec 14
2020
|
Howard Liang CFO & Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
91,900
+50.0%
|
$551,400
$6.5 P/Share
|
|
Dec 14
2020
|
Howard Liang CFO & Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,405,300
+47.17%
|
$0
$0.5 P/Share
|
|
Dec 11
2020
|
John Oyler Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
545,597
+50.0%
|
-
|
|
Dec 11
2020
|
John Oyler Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
2,136,914
-12.63%
|
-
|
|
Dec 10
2020
|
Xiaodong Wang Director |
BUY
Bona fide gift
|
Indirect |
1,244,542
+50.0%
|
-
|
|
Dec 10
2020
|
Xiaodong Wang Director |
SELL
Bona fide gift
|
Direct |
1,332,552
-9.36%
|
-
|
|
Dec 04
2020
|
Donald W. Glazer Director |
SELL
Bona fide gift
|
Direct |
589,849
-16.86%
|
-
|
|
Dec 04
2020
|
Baker Bros. Advisors LP |
SELL
Open market or private sale
|
Indirect |
1,511,546
-11.36%
|
$332,540,120
$220.5 P/Share
|
|
Nov 30
2020
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-29.69%
|
$402,000
$268.94 P/Share
|
|
Nov 30
2020
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
Oct 29
2020
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-80.74%
|
$450,000
$300.7 P/Share
|
|
Oct 29
2020
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
Oct 16
2020
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Indirect |
5,000
-100.0%
|
$1,600,000
$320.0 P/Share
|
|
Oct 13
2020
|
Baker Bros. Advisors LP |
SELL
Bona fide gift
|
Direct |
27,032
-56.47%
|
-
|
|
Oct 05
2020
|
Howard Liang CFO & Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
14,000
-30.64%
|
$4,172,000
$298.89 P/Share
|
|
Oct 05
2020
|
Howard Liang CFO & Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,000
+50.0%
|
$84,000
$6.5 P/Share
|
|
Oct 05
2020
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
4,000
-100.0%
|
$1,200,000
$300.0 P/Share
|
|
Oct 05
2020
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Indirect |
5,000
-100.0%
|
$1,500,000
$300.0 P/Share
|